Timing, route, and dose of administration of heparin-binding epidermal growth factor–like growth factor in protection against intestinal ischemia-reperfusion injury
- 1 November 2005
- journal article
- research article
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 40 (11) , 1741-1747
- https://doi.org/10.1016/j.jpedsurg.2005.07.064
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Heparin-Binding EGF-Like Growth Factor (HB-EGF) Decreases Oxygen Free Radical Production In Vitro and In VivoAntioxidants and Redox Signaling, 2002
- Heparin-Binding EGF-Like Growth Factor Down Regulates Proinflammatory Cytokine-Induced Nitric Oxide and Inducible Nitric Oxide Synthase Production in Intestinal Epithelial CellsNitric Oxide, 2002
- Heparin-Binding EGF-Like Growth Factor Decreases Inducible Nitric Oxide Synthase and Nitric Oxide Production After Intestinal Ischemia/Reperfusion InjuryAntioxidants and Redox Signaling, 2001
- N-arginine dibasic convertase is a specific receptor for heparin-binding EGF-like growth factor that mediates cell migrationThe EMBO Journal, 2001
- Heparin-Binding Epidermal Growth Factor-Like Growth Factor Protects Rat Intestine from Ischemia/Reperfusion InjuryJournal of Surgical Research, 1999
- Production of Glycosylated Heparin-Binding EGF-like Growth Factor in HeLa Cells Using Vaccinia VirusProtein Expression and Purification, 1996
- A Heparin-Binding Growth Factor Secreted by Macrophage-Like Cells That Is Related to EGFScience, 1991
- Isolation and characterization of a macrophage-derived heparin-binding growth factor.Cell Regulation, 1990
- Changes in tight junctions of rat intestinal crypt cells associated with changes in their mitotic activityTissue and Cell, 1979
- Intestinal Mucosal Lesion in Low-Flow StatesArchives of Surgery, 1970